Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Position-effect Variegation02:32

Position-effect Variegation

7.1K
In 1928, a German botanist Emil Heitz observed the moss nuclei with a DNA binding dye. He observed that while some chromatin regions decondense and spread out in the interphase nucleus, others do not. He termed them euchromatin and heterochromatin, respectively. He proposed that the heterochromatin regions reflect a functionally inactive state of the genome. It was later confirmed that heterochromatin is transcriptionally repressed, and euchromatin is transcriptionally active chromatin.
7.1K
Position and Displacement01:31

Position and Displacement

25.7K
The position of an object defines its location relative to a convenient frame of reference at any particular time. A frame of reference is an arbitrary set of axes from which the position and motion of an object are described. Earth is often used as a frame of reference, and we often describe the position of an object as it relates to stationary objects on Earth. For example, a rocket launch could be described in terms of the position of the rocket with respect to Earth as a whole. On the other...
25.7K
Serial Position Effect01:03

Serial Position Effect

539
The serial position effect is a cognitive phenomenon where individuals are more likely to recall the first and last items in a list compared to those in the middle. This effect is divided into the primacy effect and the recency effect. The primacy effect is observed when the initial items in a list are remembered better. This occurs because these items are rehearsed more frequently or receive more elaborative processing, allowing them to be encoded into long-term memory more effectively. For...
539
Positive Regulator Molecules01:45

Positive Regulator Molecules

136.1K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
136.1K
Chromatin Position Affects Gene Expression02:35

Chromatin Position Affects Gene Expression

24.8K
Chromatin is the massive complex of DNA and proteins packaged inside the nucleus. The complexity of chromatin folding and how it is packaged inside the nucleus greatly influences  access to genetic information. Generally, the nucleus' periphery is considered transcriptionally repressive, while the cell's interior is considered a transcriptionally active area. 
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
24.8K
Position Vectors01:29

Position Vectors

1.9K
A position vector is a fundamental concept in mathematics that helps determine the position of one point with respect to another point in space. It is a vector that describes the direction and distance between two points. Position vectors are highly useful in the field of math and science, as they help represent spatial relationships and make calculations easier.
For instance, we want to locate a point P(x, y, z) relative to the origin of coordinates O. In that case, we can define a position...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HER2DX genomic assay in HER2-positive early breast cancer treated with trastuzumab and pertuzumab: A correlative analysis from a real-world cohort.

Breast (Edinburgh, Scotland)·2026
Same author

Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.

Cell reports. Medicine·2026
Same author

Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer.

NPJ breast cancer·2026
Same author

Preoperative onapristone-XR in postmenopausal women with progesterone receptor-positive (PgR+)/HER2-negative early breast cancer: SOLTI-1802 ONAWA trial results.

NPJ breast cancer·2026
Same author

Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2).

NPJ breast cancer·2026
Same author

Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial.

Nature communications·2026
Same journal

Ebola at 50 - Lessons for Outbreak Response and Preparedness.

The New England journal of medicine·2026
Same journal

Ianalumab plus Eltrombopag in Immune Thrombocytopenia. Reply.

The New England journal of medicine·2026
Same journal

Ianalumab plus Eltrombopag in Immune Thrombocytopenia.

The New England journal of medicine·2026
Same journal

Hypertension Control in Low-Income Patients. Reply.

The New England journal of medicine·2026
Same journal

Hypertension Control in Low-Income Patients.

The New England journal of medicine·2026
Same journal

Hypertension Control in Low-Income Patients.

The New England journal of medicine·2026
See all related articles

Related Experiment Video

Updated: Jan 30, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.1K

Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.

Otto Metzger1, Sumithra Mandrekar2, Shom Goel3

  • 1Dana-Farber Cancer Institute, Harvard Medical School, Boston.

The New England Journal of Medicine
|January 28, 2026
PubMed
Summary
This summary is machine-generated.

Adding palbociclib to maintenance therapy significantly improved progression-free survival for patients with HER2-positive metastatic breast cancer. While effective, this combination therapy increased side effects, primarily neutropenia.

More Related Videos

An Ex vivo Model to Study Hormone Action in the Human Breast
12:31

An Ex vivo Model to Study Hormone Action in the Human Breast

Published on: January 8, 2015

12.0K
A Multimodal Imaging Framework to Advance Phenotyping of Living Label-free Breast Cancer Cells
10:37

A Multimodal Imaging Framework to Advance Phenotyping of Living Label-free Breast Cancer Cells

Published on: August 22, 2025

1.2K

Related Experiment Videos

Last Updated: Jan 30, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.1K
An Ex vivo Model to Study Hormone Action in the Human Breast
12:31

An Ex vivo Model to Study Hormone Action in the Human Breast

Published on: January 8, 2015

12.0K
A Multimodal Imaging Framework to Advance Phenotyping of Living Label-free Breast Cancer Cells
10:37

A Multimodal Imaging Framework to Advance Phenotyping of Living Label-free Breast Cancer Cells

Published on: August 22, 2025

1.2K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Standard first-line treatment for hormone-receptor-positive, HER2-positive metastatic breast cancer involves dual anti-HER2 therapy, chemotherapy, and maintenance HER2-targeted and endocrine therapies.
  • Palbociclib, a CDK4/6 inhibitor, shows potential to overcome resistance to endocrine and HER2-directed therapies based on preclinical and clinical data.

Purpose of the Study:

  • To evaluate the efficacy and safety of adding palbociclib to maintenance HER2-targeted and endocrine therapies in patients with hormone-receptor-positive, HER2-positive metastatic breast cancer.
  • To assess the impact on progression-free survival (PFS) as the primary endpoint.

Main Methods:

  • Phase 3, open-label, randomized trial (PATINA) involving 518 patients with hormone-receptor-positive, HER2-positive metastatic breast cancer.
  • Patients received maintenance HER2-targeted and endocrine therapies with or without palbociclib in a 1:1 ratio after initial chemotherapy.
  • Primary endpoint: investigator-assessed progression-free survival; Secondary endpoints: objective response, clinical benefit, safety, and overall survival.

Main Results:

  • Palbociclib group showed significantly longer progression-free survival (median 44.3 months vs. 29.1 months; HR 0.75; P=0.02) compared to standard therapy.
  • Higher rates of Grade 3 and 4 adverse events, predominantly neutropenia, were observed in the palbociclib group (79.7% and 10.0%) versus the standard therapy group (30.6% and 3.6%).

Conclusions:

  • Addition of palbociclib to maintenance anti-HER2 and endocrine therapies significantly improves progression-free survival in this patient population.
  • The improved PFS comes with increased toxicity, primarily neutropenia, highlighting a trade-off between efficacy and safety.